抽象的
目标血液嗜酸性粒细胞计数对慢性阻塞性肺疾病(COPD)发展的影响尚不清楚。我们调查了较高的血液嗜酸性粒细胞计数是否与大量在基线时患有肺部疾病的男性和女性中患有阻塞性肺疾病(旧)的风险有关。
方法This was a cohort study of 359 456 Korean adults without a history of asthma and without OLD at baseline who participated in health screening examinations including spirometry. OLD was defined as pre-bronchodilator forced expiratory volume in 1 s (FEV1)/强制生命能力(FVC)<0.7和FEV1<80% predicted.
结果After a median (interquartile range) follow-up of 5.6 (2.9–9.2) years, 5008 participants developed incident OLD (incidence rate 2.1 (95% CI 2.1–2.2) per 1000 person-years). In the fully adjusted model, the hazard ratios for incident OLD comparing eosinophil counts of 100– <200, 200– <300, 300– <500 and ≥500versus<100 cells·μL−1为1.07(95%CI 1.00–1.15),1.30(95%CI 1.20-1.42),1.46(95%CI 1.33–1.60)和1.72(分别为95%CI 1.51-1.95)(Ptrend<0.001)。这些关联在临床相关的亚组中是一致的,包括永无止境的吸烟者和目前的吸烟者。
结论In this large longitudinal cohort study, blood eosinophil counts were positively associated with the risk of developing of OLD. Our findings indicate a potential role of the eosinophil count as an independent risk factor for developing COPD.
抽象的
Blood eosinophil counts were positively associated with the risk of developing obstructive lung disease in a large longitudinal cohort of young and middle-aged men and womenhttps://bit.ly/37QeCeW
脚注
本文具有可用的补充材料www.qdcxjkg.com
This article has an editorial commentary:https://doi.org/10.1183/13993003.01105-2021
作者贡献:概念和设计:H.Y。Park,Y。Chang,J。Cho和S. Ryu。实验和数据采集:Y. Chang,J。Ahn,E。Guallar,J。Cho和S. Ryu。分析和解释:H.Y。Park,Y。Chang,D。Kang,Y.S。Hong,D。Zhao,J。Ahn,D。Singh,E。Guallar,J。Cho和S. Ryu。起草手稿:H.Y。Park,Y。Chang,S.H。Shin,D。Singh,E。Guallar,J。Cho和S. Ryu。手稿的批判性修订:H.Y。 Park, Y. Chang, D. Kang, Y.S. Hong, D. Zhao, J. Ahn, S.H. Shin, D. Singh, E. Guallar, J. Cho and S. Ryu. All authors contributed to and approved the final draft of the manuscript.
利益冲突:H.Y。公园没有什么可披露的。
Conflict of interest: Y. Chang has nothing to disclose.
利益冲突:D。Kang没有什么可披露的。
Conflict of interest: Y.S. Hong has nothing to disclose.
Conflict of interest: D. Zhao has nothing to disclose.
Conflict of interest: J. Ahn has nothing to disclose.
Conflict of interest: S.H. Shin has nothing to disclose.
利益冲突:D。Singh报告了阿斯利康,Boehringer Ingelheim,Chiesi,Cipla,Cipla,Genentech,GlaxoSmithkline,GlaxoSmithkline,Glenmark,Gossamerbio,Menarini,Menarini,Mundipharma,Novartis,Novartis,Peptinnovate,Peptinnovate,Pfizer,Pfizer,Pfizer,Pulmatrix,Theravance,Thravance和Verona,Fersext offerone,fornona offerona,
利益冲突:E。Guallar无话可说。
利益冲突:j .赵disclo无关se.
利益冲突:S。Ryu无话可说。
Support statement: This article was supported by the SKKU Excellence in Research Award Research Fund, Sungkyunkwan University, 2020. D. Singh is supported by the National Institute for Health Research (NIHR) Manchester Biomedical Research Centre (BRC). Funding information for this article has been deposited with theCrossref Funder Registry.
- 已收到2020年10月13日。
- Accepted2021年2月22日。
- 版权所有©作者2021。用于复制权和权限联系权限{at} ersnet.org